UK-based software provider to the life science industry, Veratrak, has announced its partnership with French contract development and manufacturing organisation (CDMO) Skyepharma.
Skyepharma is a fully integrated CDMO offering early formulation development, scale up, manufacturing and packaging of classic and complex oral solid dosage forms.
The company has selected Veratrak’s platform to ensure data integrity and enable secure data sharing throughout its supply chain. Skyepharma will leverage Veratrak to exchange and collaborate on quality and manufacturing records with their supply chain partners. Veratrak’s built-in compliance with EU GMP Annex 11 and FDA 21 CFR Part 11 electronic signatures was also a key factor in cementing the partnership.
Aline Moulin, Pharmaceutical Development Director at Skyepharma, said: “The pharmaceutical industry is highly regulated so it was important for us to choose a fully compliant solution that could also add value to our supply chain.
“We chose to partner with Veratrak as the platform will provide us the ability to streamline the onboarding of new customers and securely exchange manufacturing, quality, and analytical data with them. Data integrity was a key driver behind our choice, and the Veratrak solution will enable us to store and share data securely throughout our operations and those of our supply chain partners.
“We are excited to work with Veratrak and reap the benefits of the platform as well as see the positive impact this has for our supply chain network. We expect to see improved internal processes as the data passed between partners will now be verified and easily traceable.”
The Veratrak platform leverages blockchain to store data as part of an immutable ledger, providing an auditable, compliant solution for critical document transfer and safeguarding data security. Using the platform, contract service organisations and life science companies can securely store and share data across partners in the supply chain, gaining visibility to collaborative processes with their partners.
The cloud-based software as a solution (SaaS) product can be seamlessly integrated into existing internal systems, like enterprise ERP software, which means implementation is quick and straightforward. Veratrak’s reporting capabilities will give Skyepharma insight into KPIs like lead time and right-first-time percentage to capture quality and efficiency gains.
Jason Lacombe, CEO of Veratrak, said: “We are delighted to welcome Skyepharma to the Veratrak platform. We’re looking forward to helping the company and its partners benefit from full visibility of supply chain operations, including critical processes such as document and data sharing.
“It is key that the integrity of data is ensured as it is shared between partners. Using the platform will allow Skyepharma to have full oversight of data, including an indisputable audit trail of data and document processes.”
The Veratrak platform is purpose-built for the life science industry and is being continuously developed by industry experts, enabling the firm to provide a digital solution that solves unmet market challenges.
About Veratrak
Veratrak is a software provider for the life science industry which offers secure and compliant document transfer and facilitates collaboration between supply chain partners to generate efficiencies across operations. With the aim to move companies from paper to platform, its solution was developed by experts and aims to drive a digital transformation to create a safer, more secure future for the industry’s critical supply chains.
Veratrak is supported by an advisory board with vast experience across the pharma industry, as well as insight into the supply chain, packaging, digital operations and new technologies. The company is at the forefront of blockchain technology and its use in the pharmaceutical industry to benefit security, collaboration and operational performance.
About Skyepharma
Skyepharma is a fully integrated CDMO offering early formulation development, scale up, manufacturing and packaging of classic and complex oral solid dosage forms.
Aline MOULIN was awarded by the National Graduate Chemistry School of Montpellier and received her M. Sc. Degree in Biomolecular Chemistry from the University of Montpellier in 2004. She then achieved her PhD at the Institut des Biomolecules Max Mousseron in Montpellier. She was appointed Medicinal Chemistry Research Scientist in 2007 at Sanofi Research Center (Vitry sur Seine, France). She joined Flamel Technologies (Lyon, France) R&D team in 2009 to work on the design, development and industrialization of drug delivery systems. In 2018, she joined Skyepharma as Senior Project Manager and was appointed Pharmaceutical Development Director in 2020.
